[{"orgOrder":0,"company":"Ingenza","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ingenza Meets a Key Milestone in the Deployment of Novel Cost-Effective Covid-19 Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Ingenza","sponsor":"Amplifica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ingenza Collaborates with Amplifica to Advance Novel Alopecia Treatments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Ingenza
Amplifica has partnered with Ingenza to advance the development of its signalling molecules, which stimulate dormant hair follicle stem cells and result in the active regrowth of hairs, from proof of concept through toxicology and clinical trials.